pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jun 12·1 min read
save

AstronauTx appoints Michelle Mellion as new chief medical officer

Jun 12, 2026·read at STAT ↗Positive

STAT+ columnist Ed Silverman reports on the latest personnel moves in the pharmaceutical sector, a regular feature that tracks hires, promotions and departures.

The most recent addition is Michelle Mellion, who joins AstronauTx as chief medical officer. The appointment was announced in the June 12, 2026 column.

Mellion comes to AstronauTx after serving as chief medical officer at PepGen and EveryONE Medicines, bringing experience from both companies to her new role.

The hire reflects ongoing talent shifts as firms seek to strengthen their medical leadership amid evolving drug development and pricing challenges.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Up and down the ladder: The latest comings and goings”

read at STAT ↗
454 words · retrieved Jun 12
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
ASTRAZENECANOVORISINGSanofi
drugs
Obesity2
topics
Obesity2Drug ShortageOncology

related stories

  • 3d ago5 biggest venture capital raises of Q3 2026BioSpace
  • Jun 12STAT+: Pharmalittle: We’re reading about a discontinued cancer drug, a Novo security breach, and moreSTAT
  • 4d agoThe top biopharma conferences in 2027BioPharma Dive
  • Aug 28STAT+: Pharmalittle: We’re reading about an AstraZeneca trial failure, a ‘monstrous’ conflict of interest, and moreSTAT
  • Jul 2STAT+: Pharmalittle: We’re reading about a court win for Amgen, Novo seeking supplier discounts, and moreSTAT